Evidence map›Paper›PMID 33729494›Full record

ArticleJournal of the National Cancer Institute2021

Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.

Lari Wenzel, Kathryn Osann, Chelsea McKinney, David Cella, Giulia Fulci, Mary J Scroggins, Heather A Lankes, Victoria Wang, Kenneth P Nephew, George L Maxwell and 17 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Heterogeneity and treatment landscape of ovarian carcinoma.Nature reviews. Clinical oncology · 2023
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 20 institutions in 2 countries.

Lari WenzelDepartment of Medicine and Program in Public Health, University of California, Irvine, CA, USA.ORCID 0000-0002-3393-0349
Kathryn OsannDepartment of Medicine and Program in Public Health, University of California, Irvine, CA, USA.ORCID 0000-0003-1364-7367
Chelsea McKinneyDepartment of Medicine and Program in Public Health, University of California, Irvine, CA, USA.
David CellaDepartment of Medical Social Sciences, Northwestern University Health System, Chicago, IL, USA.
Giulia FulciGlaxoSmithKline; Waltham, MA, USA.
Mary J ScrogginsInternational Gynecology Cancer Society, Austin, TX, USA.
Heather A LankesNRG Oncology, Philadelphia, PA, USA.
Victoria WangDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-4079-5576
Kenneth P NephewMedical Sciences Program, Indiana University School of Medicine-Bloomington, Bloomington, IN, USA.ORCID 0000-0003-2192-1346
George L MaxwellWomen's Health Integrated Research Center at Inova Health System, Women's Service Line, Inova Health System, Falls Church, VA, USA.
Samuel C MokDepartment of Gynecological Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-7013-1805
Thomas P ConradsWomen's Health Integrated Research Center at Inova Health System, Women's Service Line, Inova Health System, Falls Church, VA, USA.
Austin MillerRoswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID 0000-0001-9739-8462
Robert S MannelStephenson Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK, USA.
Heidi J GrayGynecologic Oncology, University of Washington Medical Center, Seattle, WA, USA.
Parviz HanjaniGynecologic Oncology, Abington-Jefferson Health, Abington, PA, USA.
Warner K HuhUniversity of Alabama Highlands, Birmingham, AL, USA.
Nick SpirtosWomen's Cancer Center of Nevada, Las Vegas, NV, USA.ORCID 0000-0002-6109-2418
Mario M LeitaoMemorial Sloan Kettering Cancer and Weill Cornell Medical Center, New York, NY, USA.
Gretchen GlaserGynecologic Oncology, Mayo Clinic, Owatonna, MN, USA.ORCID 0000-0001-9413-316X
Sudarshan K SharmaAMITA Health Physicians, Hinsdale, IL, USA.
Alessandro D SantinDepartment of Obstetrics, Gynecology and Reproductive Services, Yale University School of Medicine, New Haven, CT, USA.
Paul SperdutoMinneapolis Radiation Oncology and Metro-Minnesota Community Oncology Research Consortium, St. Louis Park, MN, USA.
Shashikant B LeleRoswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Robert A BurgerGenentech, Oceanside, CA, USA.
Bradley J MonkDivision of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ, USA.ORCID 0000-0001-6985-0159
Michael BirrerWinthrop P. Rockefeller Cancer Institute University of Arkansas for Medical Sciences, Little Rock, AR, USA.
University of California, Irvine · USInova Health System · USRoswell Park Comprehensive Cancer Center · USAbington Memorial Hospital · USAmita Health · USDana-Farber Cancer Institute · USGlaxoSmithKline (United States) · USIndiana University Bloomington · USMemorial Sloan Kettering Cancer Center · USMetro-Minnesota Community Oncology Research Consortium · USNorthwestern University · USNRG Oncology · USThe University of Texas MD Anderson Cancer Center · USUniversity of Alabama · USUniversity of Arizona · USUniversity of Oklahoma · USUniversity of Washington Medical Center · USWinnMed · USWinthrop Rockefeller Foundation · USWomen's Cancer Center of Nevada · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam, GREG YOTHERS · 2014 to 2026
$146.4M
NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NRG Oncology Biospecimen BankU24CA196067 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Tanner J. Freeman, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$42.6M
A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical TrialsUG1CA233193 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Muhammad Furqan · 2019 to 2026
$13.7M
Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterUG1CA233290 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAROL AGHAJANIAN, Darren Feldman · 2019 to 2026
$10.2M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS U24 CA196067NCI NIH HHS UG1 CA189867NCI NIH HHS UG1 CA233193NCI NIH HHS UG1 CA233290
6 · The paper itself

Abstract

backgroundThere is a critical need to identify patient characteristics associated with long-term ovarian cancer survival.

methodsQuality of life (QOL), measured by the Functional Assessment of Cancer Therapy-Ovarian-Trial Outcome Index (FACT-O-TOI), including physical, functional, and ovarian-specific subscales, was compared between long-term survivors (LTS) (8+ years) and short-term survivors (STS) (<5 years) of GOG 218 at baseline; before cycles 4, 7, 13, 21; and 6 months post-treatment using linear and longitudinal mixed models adjusted for covariates. Adverse events (AEs) were compared between survivor groups at each assessment using generalized linear models. All P values are 2-sided.

resultsQOL differed statistically significantly between STS (N = 1115) and LTS (N = 260) (P < .001). Baseline FACT-O-TOI and FACT-O-TOI change were independently associated with long-term survival (odds ratio = 1.05, 95% confidence interval = 1.03 to 1.06 and odds ratio = 1.06, 95% confidence interval = 1.05 to 1.07, respectively). A 7-point increase in baseline QOL was associated with a 38.0% increase in probability of LTS, and a 9-point increase in QOL change was associated with a 67.0% increase in odds for LTS. QOL decreased statistically significantly with increasing AE quartiles (cycle 4 quartiles: 0-5 vs 6-8 vs 9-11 vs ≥12 AEs, P = .01; cycle 21 quartiles: 0-2 vs 3 vs 4-5 vs ≥6 AEs, P = .001). Further, LTS reported statistically significantly better QOL compared with STS (P = .03 and P = .01, cycles 4 and 21, respectively), with similar findings across higher AE grades.

conclusionsBaseline and longitudinal QOL change scores distinguished LTS vs STS and are robust prognosticators for long-term survival. Results have trial design and supportive care implications, providing meaningful prognostic value in this understudied population.

Indexed as

Ovarian NeoplasmsQuality of LifeCarcinoma, Ovarian EpithelialHumansPrognosisSurvivors

Identifiers

PMID33729494
PMCPMC8486331
OpenAlexW3137384774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.